Acute lung injury (ALI) is a serious respiratory disease that affects oxygen exchange and is characterized by abrupt inflammation and fluid accumulation in the lungs. It damages the alveolar-capillary membrane and can be caused directly (like pneumonia) or indirectly (like sepsis, trauma). Bilateral pulmonary infiltrates, fast breathing, and hypoxemia are among the symptoms. Neutrophil-mediated inflammation, endothelial/epithelial damage, and compromised fluid clearance are all part of the pathogenesis. The mainstays of treatment are fluid management, treating the underlying causes, and using mechanical ventilation with lung-protective techniques. Despite advancements, mortality rates are still significant. The acute lung injury pipeline analysis by Expert Market Research focuses on various treatment options for this disease. Increasing research, improved diagnostics, and innovative treatments are expected to fuel the growth of acute lung injury drug candidates in the coming years.
Major companies involved in the Acute Lung Injury pipeline analysis include Biotest and Longeveron Inc., among others.
Leading drugs currently in the pipeline include Lomecel-B, Trimodulin, and others.
Advancements in novel therapies are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Acute Lung Injury Pipeline Analysis Report by Expert Market Research gives comprehensive insights into acute lung injury therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for acute lung injury. The acute lung injury report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The acute lung injury pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with acute lung injury treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to acute lung injury.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In the pathophysiology of acute lung injury, alveolar epithelial and endothelial cells sustain widespread damage, which raises alveolar-capillary permeability and causes protein-rich pulmonary edema. Tight junctions are broken by neutrophils and inflammatory mediators, which impairs alveolar fluid clearance and causes barrier dysfunction. Damage is spread by this mismatch between pro- and anti-inflammatory reactions, which results in hypoxemia, reduced lung compliance, and compromised gas exchange. Negative results are correlated with the degree of edema clearance impairment.
To reduce ventilator-induced lung damage, supportive care combined with lung-protective mechanical ventilation is the mainstay of treatment for acute lung injury. Low tidal volumes (4–6 mL/kg projected body weight) and plateau pressures under 30 cm H₂O are used. Other tactics include conservative fluid management, prone positioning for severe instances, moderate positive end-expiratory pressure (PEEP), and extracorporeal life support in certain patients. Pharmacologic treatments haven't always decreased death rates.
With an estimated 64–86 incidents per 100,000 person-years in the United States, or roughly 190,000–200,000 cases per year, acute lung injury (ALI) is a major source of morbidity and mortality among critically sick patients. Older folks and people with risk factors including sepsis, pneumonia, or trauma are more likely to have the illness. ALI mortality is still high, ranging from 35% to 40%, despite improvements in care.
This section of the report covers the analysis of acute lung injury drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, in the Acute Lung Injury pipeline, all the candidates are equally divided in Phase I and Phase III with 50% each demonstrating a narrow spectrum of development stages and progress toward potential treatments.
The drug molecule categories covered under the Acute Lung Injury pipeline analysis include small molecules, RNA-based therapies, peptides, biologics, and gene editing therapies. The Acute Lung Injury report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Acute Lung Injury.
Biologics are emerging as promising agents in the Acute Lung Injury pipeline. For example, Lomecel-B, an allogeneic cell therapy composed of medicinal signaling cells (MSCs) derived from the bone marrow of young, healthy adult donors.
The EMR report for the acute lung injury pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Acute Lung Injury clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for acute lung injury. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of acute lung injury drug candidates.
Longeveron Inc. developed Lomecel-B, an allogeneic cell therapy made of medicinal signaling cells (MSCs) extracted from young, healthy adult donors' bone marrow. It is being studied for the treatment of acute respiratory distress syndrome (ARDS) brought on by influenza or COVID-19 in a Phase 1 clinical trial. The purpose of the study is to evaluate the safety of giving afflicted patients up to three intravenous injections of 100 million cells each. Lomecel-B is intended to reduce inflammation and encourage tissue healing in cases of lung damage.
Biotest created Trimodulin, a new polyclonal antibody treatment made up of human plasma-derived immunoglobulins IgM, IgA, and IgG. To assess its effectiveness and safety in hospitalized people with community-acquired pneumonia (CAP), including COVID-19 pneumonia, a Phase III clinical investigation is presently underway. Trimodulin is given intravenously over a period of five days with the goal of improving clinical outcomes, lowering inflammation, and modifying immunological responses in patients suffering from acute lung injury.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Acute Lung Injury Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for acute lung injury. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into acute lung injury collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share